Clinical Trial

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-19
minor Completion moved earlier: 2026-10-17 -> 2025-10-17 2026-07-19
Trial Details
NCT Number NCT03480360
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin +1 more
Enrollment 21 participants
Start Date 2018-03-28
Primary Completion 2025-02-14 (estimated)
Study Completion 2025-10-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-17